Business Context and Reporting Period
This Form 8-K was filed by Vallon Pharmaceuticals, Inc. (Nasdaq: VLON), although the request metadata identifies GRI Bio, Inc. The report concerns amendments entered into on July 25, 2022, to securities agreements originally dated May 13, 2022. It is not a periodic financial report and does not provide quarterly or annual financial results.
Material Agreement Changes
- Applicable warrant holders must exercise their warrants on a cashless basis, in whole, by August 10, 2022.
- Each Applicable Holder will receive one common share for each warrant under the alternate cashless exercise provision, replacing the prior cashless-exercise formula.
- Warrants not exercised by August 10, 2022 will be automatically exercised under the alternate cashless exercise provision.
- The Purchase Agreement was amended to remove restrictions on issuing or announcing common stock or common-stock equivalents below the applicable purchase price during specified 30-day periods.
- The Company also removed a restriction preventing it from consummating an Extraordinary Transaction before the resale registration statement for the warrant shares became effective.
Financial Metrics and Liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity measures, or other operating financial metrics.
Outlook, Risks, and Unusual Items
The amendments may facilitate additional equity issuance or an Extraordinary Transaction by removing certain financing and transaction restrictions. The filing does not provide management guidance, an operating outlook, or quantified financial impacts. The automatic exercise feature and the potential issuance of common shares may affect the Company’s share count and dilution, but the filing text does not provide the number of applicable warrants or the resulting number of shares.
Investor Verification Items
- Confirm the correct issuer: the filing identifies Vallon Pharmaceuticals, Inc., not GRI Bio, Inc.
- Review Exhibits 10.1 and 10.2 for the complete amendment terms and definitions.
- Verify the number of Applicable Holders and warrants subject to cashless or automatic exercise.
- Assess potential dilution from the one-share-per-warrant alternate cashless exercise.
- Confirm whether the applicable resale registration statement became effective and whether any Extraordinary Transaction or subsequent financing occurred.